InspireMD Inc. announced new six-month results from the MASTER trial demonstrating that the MGuard embolic protection stent (EPS) outperformed bare metal stents and drug-eluting stents in all-...
Patients with coronary artery disease who undergo treatment at the University of Maryland Medical Center (UMMC) now can receive long-term therapy based on information found in their genes. As part...
Elixir Medical Corp. announced it received CE (Conformité Européenne) mark approval for its DESolve Novolimus-eluting bioresorbable coronary stent scaffold system. The scaffold is...
University of Michigan researchers said the preliminary results of using biresorbable zinc stents were amazing, with corrosion rates exactly where they need to be for a stent successful platform...
For patients who received stents to restore blood flow through the main arteries supplying blood to the brain, inflating a tiny balloon inside the arteries after implantation of the stent ...
Boston Scientific received CE mark approval for the Promus Premier everolimus-eluting platinum chromium coronary stent system, the company's next-generation durable polymer drug-eluting stent (DES...
The interventional cardiology market includes, but is not limited to, drug-eluting stents, bare-metal stents, percutaneous transluminal coronary angioplasty (PTCA) and...
January 16, 2013 — Just weeks after the Food and Drug Administration (FDA) approved Cook Medical’s Zilver PTX drug-eluting peripheral stent, Riverside Methodist Hospital in Columbus,...
Abbott announced the initiation of the ABSORB III clinical trial in patients in the United States. The randomized controlled trial will enroll about 2,250 patients and compare the performance of...
Abbott announced that the Xience Xpedition everolimus-eluting coronary stent system received U.S. Food and Drug Administration (FDA) approval and is launching immediately in the...
